Sign in
4

Changes in Ownership

Spyre Therapeutics, Inc. Filed Acc 0001209191-21-052272

Chief Financial Officer bought 40,372 shares at an average $6.51 ($262,660)

From the SEC's structured data for this filing

Trades in this filing

Alspaugh Jonathan · Chief Financial Officer

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2021-08-16 Purchase : show line 1 in the form +9,780 $6.37 $62,275 9,780 D
2021-08-17 Purchase : show line 2 in the form +23,392 $6.50 $151,985 33,172 D
2021-08-18 Purchase : show line 3 in the form +7,200 $6.72 $48,400 40,372 D
Open-market purchases · 40,372 sh · avg $6.51 · $262,660
Loading xslF345X03/doc4.xml…